Starling Oncology (STLNW) Non Operating Income (2021 - 2026)

Starling Oncology (STLNW) has reported Non Operating Income for 6 consecutive years, with -$5.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Income rose 12.75% year-over-year to -$5.2 million; the trailing twelve-month figure through Jun 2026 stood at -$10.2 million (up 46.63% YoY), and the FY2025 full-year result was -$24.7 million, down 442.44% from the prior year.
• Non Operating Income eased to -$5.2 million in Q2 2026 per STLNW's latest filing, from $4.0 million in the prior quarter.
• Across five years, Non Operating Income topped out at $37.9 million in Q1 2022 and bottomed at -$9.7 million in Q1 2025.
• Historically, Non Operating Income has averaged $2.5 million across 5 years, with a median of -$1.6 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Non Operating Income soared 72595.83% in 2022, then tumbled 769.94% in 2025.
• Over 5 years, Non Operating Income stood at $13.7 million in 2022, then slumped by 127.58% to -$3.8 million in 2023, then surged by 66.85% to -$1.3 million in 2024, then soared by 52.04% to -$601000.0 in 2025, then plunged by 760.73% to -$5.2 million in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered -$5.2 million, $4.0 million, and -$601000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.